484 related articles for article (PubMed ID: 27566564)
1. Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance.
Avnet S; Lemma S; Cortini M; Pellegrini P; Perut F; Zini N; Kusuzaki K; Chano T; Grisendi G; Dominici M; De Milito A; Baldini N
Oncotarget; 2016 Sep; 7(39):63408-63423. PubMed ID: 27566564
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
3. Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma.
Fanelli M; Hattinger CM; Vella S; Tavanti E; Michelacci F; Gudeman B; Barnett D; Picci P; Serra M
Curr Cancer Drug Targets; 2016; 16(3):261-74. PubMed ID: 26548759
[TBL] [Abstract][Full Text] [Related]
4. Pre-treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin.
Scotlandi K; Serra M; Manara MC; Lollini PL; Maurici D; Del Bufalo D; Baldini N
Int J Cancer; 1994 Jul; 58(1):95-101. PubMed ID: 7912235
[TBL] [Abstract][Full Text] [Related]
5. Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma.
Cagliero E; Ferracini R; Morello E; Scotlandi K; Manara MC; Buracco P; Comandone A; Baroetto Parisi R; Baldini N
Oncol Rep; 2004 Nov; 12(5):1023-31. PubMed ID: 15492788
[TBL] [Abstract][Full Text] [Related]
6. TFAP2C-mediated LINC00922 signaling underpins doxorubicin-resistant osteosarcoma.
Gu Z; Zhou Y; Cao C; Wang X; Wu L; Ye Z
Biomed Pharmacother; 2020 Sep; 129():110363. PubMed ID: 32563982
[TBL] [Abstract][Full Text] [Related]
7. Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J.
Lourda M; Trougakos IP; Gonos ES
Int J Cancer; 2007 Feb; 120(3):611-22. PubMed ID: 17096323
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
Castro-Gamero AM; Borges KS; da Silva Silveira V; Lira RC; de Paula Gomes Queiroz R; Valera FC; Scrideli CA; Umezawa K; Tone LG
Anticancer Drugs; 2012 Jul; 23(6):638-50. PubMed ID: 22382389
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.
Tu B; Zhu J; Liu S; Wang L; Fan Q; Hao Y; Fan C; Tang TT
Oncotarget; 2016 Jul; 7(30):48296-48308. PubMed ID: 27340780
[TBL] [Abstract][Full Text] [Related]
10. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
11. P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma.
He C; Sun Z; Hoffman RM; Yang Z; Jiang Y; Wang L; Hao Y
Anticancer Res; 2019 Apr; 39(4):1711-1718. PubMed ID: 30952710
[TBL] [Abstract][Full Text] [Related]
12. PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma.
Ma W; Yang L; Liu H; Chen P; Ren H; Ren P
Biochem Biophys Res Commun; 2020 Jan; 521(1):204-211. PubMed ID: 31640855
[TBL] [Abstract][Full Text] [Related]
13. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
[TBL] [Abstract][Full Text] [Related]
14. Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma.
Xia YZ; Yang L; Xue GM; Zhang C; Guo C; Yang YW; Li SS; Zhang LY; Guo QL; Kong LY
Oncotarget; 2016 Aug; 7(35):56371-56382. PubMed ID: 27486760
[TBL] [Abstract][Full Text] [Related]
15. Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.
Nomura M; Rainusso N; Lee YC; Dawson B; Coarfa C; Han R; Larson JL; Shuck R; Kurenbekova L; Yustein JT
J Natl Cancer Inst; 2019 Nov; 111(11):1216-1227. PubMed ID: 30793158
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA‑22 regulates autophagy and apoptosis in cisplatin resistance of osteosarcoma.
Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Sun L; Sun C; Feng W; Guo SB
Mol Med Rep; 2020 Nov; 22(5):3911-3921. PubMed ID: 33000186
[TBL] [Abstract][Full Text] [Related]
17. HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma.
Xiao X; Wang W; Li Y; Yang D; Li X; Shen C; Liu Y; Ke X; Guo S; Guo Z
J Exp Clin Cancer Res; 2018 Aug; 37(1):201. PubMed ID: 30153855
[TBL] [Abstract][Full Text] [Related]
18. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.
Wang Z; Yang L; Xia Y; Guo C; Kong L
Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987
[TBL] [Abstract][Full Text] [Related]
19. The dynamic role of autophagy and MAPK signaling in determining cell fate under cisplatin stress in osteosarcoma cells.
Mukherjee S; Dash S; Lohitesh K; Chowdhury R
PLoS One; 2017; 12(6):e0179203. PubMed ID: 28598976
[TBL] [Abstract][Full Text] [Related]
20. PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
Higuchi T; Yamamoto J; Sugisawa N; Tashiro Y; Nishino H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(1):35-40. PubMed ID: 31882549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]